AI assistant
Getinge Interim / Quarterly Report 2026
2917_10-q_2026-04-21_b6bf0d6d-6885-49db-898a-0f798a08426a.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Q1 2026
Financial Report
GETINGE
Comments from Mattias Perjos, CEO
Organic growth, strong cash flow and regulatory milestone
"We succeeded in surpassing last year's record-breaking first quarter with organic growth in both order intake and net sales. This was despite a decline for Acute Care Therapies, primarily in ventilators, where we were highly active last year and captured shares in the wake of market consolidation. Consumables for life-supporting ECLS therapy continued to show stable growth from a leading position globally. Surgical Workflows reported a double-digit increase in its order intake following strong growth in all product categories, where equipment for operating rooms in the US particularly contributed. Life Science also noted a strong start to the year with organic sales growth of a full 16%. The overall order intake was positive but varied within the business area. The investment climate for pharma is impacted by the geopolitical uncertainty, which is primarily seen in the order intake for the project-based and capital intense product category WIS.
Adjusted EBITA margin was 11.1%, and excluding tariffs and currency effects would have been 12.6% and thus an underlying improvement on last year. This confirms the ongoing positive trend in structural profitability thanks to a steady focus on price adjustments, productivity and cost control. This is also reflected in the strong cash flow in the quarter.
We expanded the product portfolio in Life Science with a new steam sterilizer, designed for laboratory and research applications. Furthermore, an important regulatory milestone was achieved at the end of the quarter with the receipt of the CE mark for Cardiohelp II, a brand-new generation of ECLS systems. The product is developed in close collaboration with our customers and is even more user-friendly and mobile. In cardiovascular surgery, the Intergard Synergy antimicrobial vascular graft also received EU MDR approval.
We are continuing to demonstrate that we are well positioned in the prioritized product categories of our customers, which gives us confidence for the future. There is currently high geopolitical uncertainty, however, based on dialogue with our customers, we choose to maintain our forecast of organic sales growth of 3–5% in 2026."
January – March 2026 in brief
- Net sales increased organically by 0.8% (6.2) and the order intake rose by 3.9% organically (2.9)
- Adjusted gross profit amounted to SEK 3,828 M (4,337) and the margin was 51.4% (52.1)
- Adjusted EBITA was SEK 824 M (1,003) and the margin 11.1% (12.1)
- Adjusted earnings per share amounted to SEK 1.80 (2.18)
- Free cash flow amounted to SEK 842 M (160)
Outlook 2026: Net sales for 2026 are expected to increase by 3–5% organically, adjusted for the phase-out of Surgical Perfusion⁵ (Unchanged)
Summary of financial performance²
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2026 | 2025 |
| Order intake | 7,939 | 8,632 | 33,331 | 34,025 |
| Organic change, % | 3.9 | 2.9 | 3.5 | |
| Net sales | 7,443 | 8,320 | 34,092 | 34,969 |
| Organic change, % | 0.8 | 6.2 | 4.9 | |
| Adjusted gross profit | 3,828 | 4,337 | 17,099 | 17,607 |
| Margin, % | 51.4 | 52.1 | 50.2 | 50.4 |
| Adjusted EBITDA | 1,222 | 1,442 | 6,361 | 6,581 |
| Margin, % | 16.4 | 17.3 | 18.7 | 18.8 |
| Adjusted EBITA | 824 | 1,003 | 4,701 | 4,880 |
| Margin, % | 11.1 | 12.1 | 13.8 | 14.0 |
| Adjusted EBIT | 738 | 896 | 4,335 | 4,494 |
| Margin, % | 9.9 | 10.8 | 12.7 | 12.9 |
| Operating profit (EBIT) | 707 | 598 | 3,898 | 3,789 |
| Margin, % | 9.5 | 7.2 | 11.4 | 10.8 |
| Profit before tax | 573 | 428 | 3,290 | 3,145 |
| Net profit for the period | 402 | 304 | 2,374 | 2,276 |
| Adjusted net profit for the period | 490 | 597 | 2,986 | 3,093 |
| Margin, % | 6.6 | 7.2 | 8.8 | 8.8 |
| Adjusted earnings per share, SEK | 1.80 | 2.18 | 10.91 | 11.29 |
| Earnings per share, SEK | 1.47 | 1.10 | 8.66 | 8.29 |
| Cash flow from operating activities | 1,106 | 470 | 4,585 | 3,949 |
| Free cash flow | 842 | 160 | 3,334 | 2,652 |
1) For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9
2) See page 3 for calculations of adjusted performance measures
Every care has been taken in the translation of this Financial Report. In the event of discrepancies, the Swedish original will supersede the English translation.
GETINGE
- The organic order intake for Acute Care Therapies declined, mainly within ventilation where we last year had temporarily increased volumes due to market consolidation. At the same time, growth in ECLS therapy consumables was strong.
- Life Science's organic order intake increased during the quarter, partly due to recovery in Bio-Processing. WIS decreased as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
- Surgical Workflows reported a double-digit increase in organic order intake following a strong trend in all product categories.
-
Geographically, the organic order intake trend was positive in all regions.
-
Net sales for Acute Care Therapies decreased organically, mainly due to the above-mentioned reason in ventilation. Sales of ECLS therapy consumables also increased.
- Organic net sales for Life Science grew double-digit after growth in all product categories, with Sterile Transfer contributing the most.
- In Surgical Workflows, organic net sales rose following growth in primarily consumables and service in Infection Control and operating tables in Surgical Workplaces.
- Positive organic growth in EMEA, including strong performances in Italy and Germany. Sales declined in Americas and APAC
-
Recurring revenues increased in the quarter following growth in, for example, Sterile Transfer and ECLS therapy. Sales of capital goods declined in the quarter, mainly due to Critical Care and Cardiac Assist.
-
Net sales declined by SEK 877 M, corresponding to -10.5%.
- Exchange rates had an impact of SEK -901 M on sales, corresponding to -10.8%.
- Successful efforts with price adjustments and volumes had an impact of SEK +66 M on sales, corresponding to +0.8%.
Group performance
Order intake
| Order intake | Jan-Mar | Jan-Mar | Org Δ, % | R12 Mar | Jan-Dec |
|---|---|---|---|---|---|
| business areas, SEK M | 2026 | 2025 | 2026 | 2025 | |
| Acute Care Therapies | 4,256 | 4,924 | -1.2 | 17,552 | 18,220 |
| Life Science | 908 | 978 | 2.9 | 4,182 | 4,252 |
| Surgical Workflows | 2,774 | 2,730 | 13.3 | 11,597 | 11,553 |
| Total | 7,939 | 8,632 | 3.9 | 33,331 | 34,025 |
| Order intake | Jan-Mar | Jan-Mar | Org Δ, % | R12 Mar | Jan-Dec |
| --- | --- | --- | --- | --- | --- |
| regions, SEK M | 2026 | 2025 | 2026 | 2025 | |
| Americas | 3,680 | 4,085 | 4.4 | 15,024 | 15,429 |
| APAC | 1,407 | 1,531 | 6.0 | 6,187 | 6,311 |
| EMEA | 2,852 | 3,017 | 2.2 | 12,121 | 12,285 |
| Total | 7,939 | 8,632 | 3.9 | 33,331 | 34,025 |
Net sales
| Net sales | Jan-Mar | Jan-Mar | Org Δ, % | R12 Mar | Jan-Dec |
|---|---|---|---|---|---|
| business areas, SEK M | 2026 | 2025 | 2026 | 2025 | |
| Acute Care Therapies | 4,012 | 4,775 | -4.0 | 17,913 | 18,675 |
| Life Science | 1,003 | 950 | 16.0 | 4,551 | 4,498 |
| Surgical Workflows | 2,428 | 2,595 | 4.0 | 11,629 | 11,796 |
| Total | 7,443 | 8,320 | 0.8 | 34,092 | 34,969 |
| Net sales | Jan-Mar | Jan-Mar | Org Δ, % | R12 Mar | Jan-Dec |
| --- | --- | --- | --- | --- | --- |
| regions, SEK M | 2026 | 2025 | 2026 | 2025 | |
| Americas | 3,453 | 4,047 | -1.1 | 15,091 | 15,686 |
| APAC | 1,355 | 1,642 | -5.0 | 6,656 | 6,943 |
| EMEA | 2,635 | 2,630 | 7.4 | 12,345 | 12,340 |
| Total | 7,443 | 8,320 | 0.8 | 34,092 | 34,969 |
| Net sales specified by capital goods and recurring revenue, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- | --- |
| Capital goods | 2,078 | 2,481 | -6.8 | 11,565 | 11,968 |
| Recurring revenue¹) | 5,365 | 5,839 | 4.0 | 22,527 | 23,001 |
| Total | 7,443 | 8,320 | 0.8 | 34,092 | 34,969 |
¹) Consumables, service and spare parts
Net sales – bridge between Q1 2025 and Q1 2026
2 | Q1 2026 Report
GETING
- Currency effects impacted adjusted gross profit by SEK -543 M and adjusted EBITA by SEK -122 M compared with last year.
- The gross margin declined, mainly due to lower sales, negative currency effects and tariff costs.
- Adjusted EBITA fell by SEK 179 M, of which tariff costs had an impact of SEK -104 M and currency effects of SEK -122 M compared with last year. Despite continued successful price adjustments and positive mix, the margin declined 1.0 percentage point.
- Acquisition and restructuring costs are primarily related to the ongoing rationalizations in the organization.
- Net financial items decreased to SEK -135 M, mainly as a result of lower average interest year-on-year.
- The tax rate at the end of the quarter was 29.7%.
Earnings trend
| Jan-Mar 2026 | Jan-Mar 2025 | R12 Mar 2026 | Jan-Dec 2025 | |
|---|---|---|---|---|
| SEK M | ||||
| Net sales | 7,443 | 8,320 | 34,092 | 34,969 |
| Adjusted gross profit | 3,828 | 4,337 | 17,099 | 17,607 |
| Margin, % | 51.4 | 52.1 | 50.2 | 50.4 |
| Adjusted operating expenses | -2,607 | -2,895 | -10,737 | -11,026 |
| Adjusted EBITDA | 1,222 | 1,442 | 6,361 | 6,581 |
| Margin, % | 16.4 | 17.3 | 18.7 | 18.8 |
| Depreciation, amortization and write-downs of intangible assets and tangible assets^{1)} | -397 | -439 | -1,660 | -1,702 |
| Adjusted EBITA | 824 | 1,003 | 4,701 | 4,880 |
| Margin, % | 11.1 | 12.1 | 13.8 | 14.0 |
| A Amortization and write-down of acquired intangible assets^{1)} | -87 | -107 | -366 | -386 |
| Adjusted EBIT | 738 | 896 | 4,335 | 4,494 |
| Margin, % | 9.9 | 10.8 | 12.7 | 12.9 |
| B Acquisition and restructuring costs | -30 | -298 | -130 | -397 |
| C Other items affecting comparability^{2)} | - | - | -307 | -307 |
| Operating profit (EBIT) | 707 | 598 | 3,898 | 3,789 |
| Net financial items | -135 | -170 | -608 | -644 |
| Profit before tax | 573 | 428 | 3,290 | 3,145 |
| Adjusted profit before tax (adjusted for A, B and C) | 690 | 833 | 4,093 | 4,236 |
| Margin, % | 9.3 | 10.0 | 12.0 | 12.1 |
| Taxes | -170 | -124 | -916 | -869 |
| D Tax on adjustment items^{2)} | -29 | -112 | -191 | -273 |
| Adjusted net profit for the period (adjusted for A, B, C and D) | 490 | 597 | 2,986 | 3,093 |
| Margin, % | 6.6 | 7.2 | 8.8 | 8.8 |
| Of which, attributable to Parent Company shareholders | 489 | 593 | 2,972 | 3,076 |
| Average number of shares, thousands | 272,370 | 272,370 | 272,370 | 272,370 |
| Adjusted earnings per share, SEK (adjusted for A, B, C and D) | 1.80 | 2.18 | 10.91 | 11.29 |
1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs)
2) See Note 6 Adjustment items
- Adjusted EBITA for Acute Care Therapies declined by SEK 249 M, mainly due to negative currency and tariff effects as well as lower sales. This was despite continued successful price adjustments and a favorable mix. The margin fell by 2.2 percentage points.
- Life Science's adjusted EBITA increased by SEK 43 M, mainly attributable to a favorable mix and price adjustments. The margin increased by 4.1 percentage points.
- Adjusted EBITA for Surgical Workflows increased by SEK 26 M, mainly due to price adjustments and higher sales volumes. The margin improved by 1.2 percentage points.
- Costs in Group functions and other were largely unchanged year-on-year.
Adjusted EBITA per business area
| Jan-Mar 2026 | Jan-Mar 2025 | R12 Mar 2026 | Jan-Dec 2025 | |
|---|---|---|---|---|
| SEK M | ||||
| Acute Care Therapies | 763 | 1,012 | 3,514 | 3,763 |
| Margin, % | 19.0 | 21.2 | 19.6 | 20.2 |
| Life Science | 96 | 53 | 533 | 490 |
| Margin, % | 9.6 | 5.5 | 11.7 | 10.9 |
| Surgical Workflows | 75 | 49 | 1,104 | 1,077 |
| Margin, % | 3.1 | 1.9 | 9.5 | 9.1 |
| Group functions and other (incl. eliminations) | -110 | -110 | -450 | -450 |
| Total | 824 | 1,003 | 4,701 | 4,880 |
| Margin, % | 11.1 | 12.1 | 13.8 | 14.0 |
1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability
Adjusted EBITA – bridge between Q1 2025 and Q1 2026
3 | Q1 2026 Report
GETINGE
- Adjusted operating expenses for selling and administration fell by 6.8%. Organically they increased by 3.0%, mainly due to higher sales activities.
-
The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.
-
Costs for R&D were 2.9% lower year-on-year.
- Capitalized development costs were 11.9% lower compared with last year.
- The year-on-year difference was mainly due to lower costs for quality-related efforts.
-
Amortization and write-down of capitalized development costs amounted to SEK -84 M (-100), whereof SEK 0 M write-down (0).
-
Exchange-rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK -543 M compared with last year, of which SEK -395 M in translation effects and SEK -148 M in transaction effects.
-
The change in adjusted EBITA attributable to currency effects was SEK -122 M, of which SEK -97 M arose from translation effects and SEK -25 M from the net of transaction effects, and revaluation of operating receivables and liabilities in foreign currency.
-
Compared with last year, free cash flow was positively impacted by operating profit and changes in working capital, mainly due to changes in inventories and accounts payable.
- The financial position remains solid.
Adjusted operating expenses
(excluding depreciation, amortization and write-downs and other items affecting comparability)¹)
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2026 | 2025 |
| Selling expenses | -1,277 | -1,404 | -5,217 | -5,345 |
| Administrative expenses | -1,034 | -1,075 | -4,141 | -4,182 |
| Selling and administrative expenses | -2,311 | -2,479 | -9,358 | -9,527 |
| Research and development costs | -308 | -301 | -1,252 | -1,244 |
| Other operating income and expenses | 12 | -115 | -127 | -255 |
| Total | -2,607 | -2,895 | -10,737 | -11,026 |
¹) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability
Research and development
| SEK M | Jan-Mar 2026 | Jan-Mar 2025 | R12 Mar 2026 | Jan-Dec 2025 |
|---|---|---|---|---|
| Research and development costs | -463 | -477 | -1,907 | -1,921 |
| Amortization, depreciation and write-downs | -19 | -17 | -177 | -175 |
| Research and development costs, gross | -482 | -494 | -2,085 | -2,096 |
| In relation to net sales, % | 6.5 | 5.9 | 6.1 | 6.0 |
| Capitalized development costs | 155 | 176 | 622 | 643 |
| In relation to net sales, % | 2.1 | 2.1 | 1.8 | 1.8 |
| Research and development costs, net | -328 | -318 | -1,462 | -1,452 |
| Amortization and write-down of capitalized development costs¹) | -84 | -100 | -414 | -430 |
¹) Capitalized development projects
Currency impact
| Jan-Mar | R12 Mar | |
|---|---|---|
| SEK M | 2026 | 2026 |
| Net sales | -901 | -3,200 |
| Adjusted gross profit | -543 | -1,833 |
| Adjusted EBITDA | -153 | -840 |
| Adjusted EBITA | -122 | -724 |
| Adjusted EBIT | -108 | -690 |
Cash flow and financial position¹)
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2026 | 2025 |
| Cash flow before changes in working capital | 864 | 1,132 | 4,869 | 5,137 |
| Changes in working capital | 242 | -662 | -284 | -1,188 |
| Net investments in non-current assets | -264 | -310 | -1,251 | -1,297 |
| Free cash flow | 842 | 160 | 3,334 | 2,652 |
| Net interest-bearing cash/debt | 9,268 | 9,731 | 9,268 | 9,840 |
| In relation to adjusted EBITDA²) R12M, multiple | 1.5 | 1.4 | 1.5 | 1.5 |
| Net interest-bearing cash/debt, excl. pension provisions | 6,968 | 7,279 | 6,968 | 7,482 |
| In relation to adjusted EBITDA²) R12M, multiple | 1.1 | 1.1 | 1.1 | 1.1 |
¹) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures
4 | Q1 2026 Report
GETING
Sustainability developments
This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The aim is to continuously work to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.
- Getinge's energy efficiency measures are continuing to yield results in terms of both energy consumption and lower Scope 1 & 2 emissions from production facilities. The increase in the share of renewable electricity and gas in the first quarter also generated positive effects in the form of reduced emissions.
- Water consumption is mainly related to testing in production and therefore varies over time. The rising trend in the outcome for R12 March 2026 was due to increased production activity and an identified and repaired leak at one of Getinge's facilities.
- The Work Related Accident Rate (WRAR) continued to show a positive trend in the outcome for R12 March 2026.
- From 2026, the definition of the regulatory compliance KPI has been revised to focus on major observations from regulators and notified bodies only. Consequently, the regulatory compliance target has been updated from $\leq 1.5$ audit findings to $\leq 1.2$ audit findings.
- From 2026, the KPI for training in business ethics represents the percentage of employees who completed Getinge's new Code of Conduct workshop. Accordingly, the outcome represents only Jan-Mar 2026. The target remains that all employees are properly trained in business ethics.
| Key areas | R12 Mar 2026^{1)} | R12 Mar 2025^{1)} | Δ, %^{2)} | Jan-Dec 2025 | Δ, %^{3)} |
|---|---|---|---|---|---|
| Environment, Climate & Energy | |||||
| Scope 1 & 2 GHG emissions in production, ton CO_{2} equivalents^{4)} | 4,708 | 5,310 | -11.3 | 4,913 | -4.2 |
| Total energy consumption in production, MWh^{5)} | 79,674 | 82,341 | -3.2 | 80,887 | -1.5 |
| Percentage of renewable energy of total energy, %^{5)} | 70 | 67 | 3.0* | 69 | 1.0* |
| Water consumption in sites located in water scarce areas, m^{4, 6)} | 120,719 | 102,376 | 17.9 | 114,691 | 5.3 |
| Social | |||||
| Own workforce | |||||
| Employee engagement, %^{5)} | 73 | 71 | 2.0* | 73 | 0.0* |
| Percentage of female employees, %^{6)} | 38.4 | 37.7 | 0.7* | 38.2 | 0.2* |
| Percentage of female managers, %^{6)} | 34.8 | 34.3 | 0.5* | 34.1 | 0.7* |
| Work Related Accident Rate, WRAR^{9)} | 0.48 | 0.95 | -0.5 | 0.59 | -0.1 |
| Consumers and end-users | |||||
| Regulatory compliance, audit findings per audit for quality systems^{7)} | 0.8 | - | - | 0.7 | 9.6 |
| Product quality, field actions per SEK billion in net revenue | 0.8 | 1.3 | -36.9 | 1.0 | -15.5 |
| Online customer training | 52,525 | 49,951 | 5.2 | 53,238 | -1.3 |
| Governance | |||||
| Business ethics | |||||
| Percentage of employees who completed training in business ethics, %^{8)} | 49 | - | - | - | - |
*) Change in percentage points
1) R12 = Rolling 12 months
2) Index R12 Mar 2026/ R12 Mar 2025
3) Index R12 Mar 2026/ Jan-Dec 2025
4) The production sites in scope are those located in areas with high or extremely high water stress according to the WRI Water Risk Atlas tool Acqueduct, which are eight sites. One of these sites was incorrectly stated in Getinge's 2025 Sustainability Report as being located in Rastatt, Germany. The correct location is Hechingen, Germany
5) Measured and updated every six months
6) Amount at end of period
7) Data available from 2025. According to the previous definition of the KPI, the outcome was 1.4 audit findings for the full-year 2025
8) Outcome for Jan-Mar 2026. The outcome for the previous training in business ethics was $92\%$ for the full-year 2025
9) Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix, joined the Group by acquisition, and data was updated in 2025. See Getinge's Annual Report 2025 for more information
Total energy consumption in production, MWh
Scope 1 & 2 GHG emissions in production, ton CO2 equivalents
Product quality, field actions per SEK billion in net revenue
5 | Q1 2026 Report
GETINGE
Acute Care Therapies
- The organic order intake for Acute Care Therapies declined, mainly within ventilation where we last year had temporarily increased volumes due to market consolidation. At the same time, growth in ECLS therapy consumables was strong.
-
Geographically, the organic order intake increased strongly in APAC, with the main contributions from India and China. The decline in Americas was mainly attributable to market consolidation in ventilation in the US.
-
Net sales for Acute Care Therapies decreased organically, mainly due to the above-mentioned reason in ventilation. Sales of ECLS therapy consumables also increased.
- Sales grew organically in EMEA following a particularly positive trend in ECLS therapy, anesthesia and ventilation. The decline in Americas was mainly attributable to market consolidation in ventilation in the US.
-
Recurring revenue was largely unchanged, while sales of capital goods declined organically, mainly due to Critical Care and Cardiac Assist.
-
The adjusted gross margin declined by 0.4 percentage points, largely due to negative currency and tariff effects as well as lower sales volumes.
- Adjusted selling and administrative expenses increased organically by 1.7%. Inorganically, these expenses fell by 8.9%.
- Adjusted EBITA for Acute Care Therapies declined by SEK 249 M, mainly due to negative currency and tariff effects as well as lower sales. This was despite continued successful price adjustments and a favorable mix. The margin fell by 2.2 percentage points.
- Currency effects impacted sales by SEK -531 M, adjusted gross profit by SEK -346 M and adjusted EBITA by SEK -93 M compared with last year.
Acute Care Therapies
Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.
Order intake and net sales
| Order intake regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
|---|---|---|---|---|---|
| Americas | 2,197 | 2,747 | -7.2 | 9,241 | 9,791 |
| APAC | 895 | 949 | 9.1 | 3,528 | 3,583 |
| EMEA | 1,165 | 1,228 | 4.5 | 4,783 | 4,846 |
| Total | 4,256 | 4,924 | -1.2 | 17,552 | 18,220 |
| Net sales regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- | --- |
| Americas | 2,089 | 2,650 | -8.5 | 9,331 | 9,893 |
| APAC | 848 | 1,024 | -3.9 | 3,753 | 3,928 |
| EMEA | 1,076 | 1,101 | 7.0 | 4,829 | 4,854 |
| Total | 4,012 | 4,775 | -4.0 | 17,913 | 18,675 |
1) Consumables, service and spare parts
Earnings trend
| SEK M | Jan-Mar 2026 | Jan-Mar 2025 | R12 Mar 2026 | Jan-Dec 2025 |
|---|---|---|---|---|
| Net sales | 4,012 | 4,775 | 17,913 | 18,675 |
| Adjusted gross profit | 2,414 | 2,894 | 10,417 | 10,897 |
| Margin, % | 60.2 | 60.6 | 58.2 | 58.4 |
| Adjusted EBITDA | 962 | 1,236 | 4,341 | 4,616 |
| Margin, % | 24.0 | 25.9 | 24.2 | 24.7 |
| Depreciation, amortization and write-downs of intangible assets and tangible assets | -199 | -224 | -827 | -853 |
| Adjusted EBITA | 763 | 1,012 | 3,514 | 3,763 |
| Margin, % | 19.0 | 21.2 | 19.6 | 20.2 |
1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability
Events in the business area in the quarter
- A key milestone was achieved with receipt of the CE mark for Cardiohelp II, the next evolution of the transportable extracorporeal life support (ECLS) system.
- EU MDR certification for Intergard Synergy, a permanent antimicrobial vascular graft intended for replacement of arteries in the body. Intergard Synergy is a Drug Combination Device, coated two active substances, silver acetate and triclosan, to prevent risk of infection in relation to surgery.
6 | Q1 2026 Report
GETINGE
Life Science
Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.
- Life Science's organic order intake increased during the quarter, mainly related to Nuclear and Bio-Processing. WIS decreased as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
-
The organic order intake increased in Americas and APAC but declined in EMEA, mainly related to WIS.
-
Organic net sales for Life Science grew double-digit after growth in all product categories, with Sterile Transfer contributing the most.
- Organic sales increased in all regions, with Sterile Transfer the main contributor in EMEA and APAC, while WIS was the main contributor in Americas.
-
Recurring revenue and capital goods reported double-digit growth. Sterile Transfer contributed strongly to both categories, where sales of the hardware DPTE®-Alpha Port enables future sales of the consumable DPTE®-BetaBag.
-
The adjusted gross margin declined by 1.8 percentage points, mainly due to negative currencies and tariff effects.
- Adjusted selling and administrative expenses increased organically by 1.7%. Inorganically, these expenses fell by -6.4%.
- Life Science's adjusted EBITA increased by SEK 44 M, mainly attributable to a favorable mix and price adjustments. The margin increased by 4.1 percentage points.
- Currency effects impacted sales by SEK -100 M, adjusted gross profit by SEK -57 M and adjusted EBITA by SEK -11 M compared with last year.
Order intake and net sales
| Order intake regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
|---|---|---|---|---|---|
| Americas | 358 | 336 | 23.6 | 1,492 | 1,469 |
| APAC | 138 | 108 | 45.5 | 550 | 520 |
| EMEA | 412 | 534 | -18.7 | 2,141 | 2,263 |
| Total | 908 | 978 | 2.9 | 4,182 | 4,252 |
| Net sales regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- | --- |
| Americas | 381 | 369 | 18.9 | 1,672 | 1,660 |
| APAC | 104 | 108 | 10.0 | 598 | 603 |
| EMEA | 518 | 473 | 15.1 | 2,280 | 2,235 |
| Total | 1,003 | 950 | 16.0 | 4,551 | 4,498 |
| Net sales specified by capital goods and recurring revenue, SEK M | |||||
| --- | --- | --- | --- | --- | --- |
| Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 | |
| Capital goods | 326 | 312 | 15.4 | 1,887 | 1,872 |
| Recurring revenue^{1)} | 676 | 638 | 16.4 | 2,664 | 2,626 |
| Total | 1,003 | 950 | 16.0 | 4,551 | 4,498 |
1) Consumables, service and spare parts
Earnings trend
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2026 | 2025 |
| Net sales | 1,003 | 950 | 4,551 | 4,498 |
| Adjusted gross profit | 377 | 374 | 1,679 | 1,676 |
| Margin, % | 37.6 | 39.4 | 36.9 | 37.3 |
| Adjusted EBITDA | 146 | 108 | 749 | 712 |
| Margin, % | 14.5 | 11.4 | 16.5 | 15.8 |
| Depreciation, amortization and write-downs of intangible assets and tangible assets | -50 | -56 | -216 | -222 |
| Adjusted EBITA | 96 | 53 | 533 | 490 |
| Margin, % | 9.6 | 5.5 | 11.7 | 10.9 |
1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability
Events in the business area in the quarter
- Getinge Lancer LSS 700 was launched, a new addition to Getinge's steam sterilizer series. Designed for use in laboratory and research facilities, the product offers a larger chamber to efficiently process high-capacity equipment such as bioreactors.
7 | Q1 2026 Report
GETINGE
Surgical Workflows
Surgical Workflows reports and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.
- Surgical Workflows reported a double-digit increase in organic order intake following a strong trend in all product categories.
-
Growth was particularly strong in North America, mainly in consumables in Infection Control and operating room equipment in Surgical Workplaces.
-
In Surgical Workflows, organic net sales rose following growth in primarily consumables and service in Infection Control and operating tables in Surgical Workplaces.
- Geographically, growth was high in Americas and EMEA. The volatile sales profile in Digital Health Solutions was the main reason for the decline in APAC.
-
Growth in recurring revenue while capital goods declined, mainly in Infection Control.
-
The adjusted gross margin increased by 1.6 percentage points, mainly attributable to continued successful price adjustments and higher sales volumes.
- Adjusted selling and administrative expenses increased organically by 5.4%, mainly as a result of higher sales activities. Inorganically, these expenses fell by 4.3%.
- Adjusted EBITA for Surgical Workflows increased by SEK 27 M, mainly due to price adjustments and higher sales volumes. The margin improved by 1.2 percentage points.
- Currency effects impacted sales by SEK -270 M, adjusted gross profit by SEK -140 M and adjusted EBITA by SEK -24 M compared with last year.
Order intake and net sales
| Order intake regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
|---|---|---|---|---|---|
| Americas | 1,125 | 1,001 | 29.5 | 4,291 | 4,168 |
| APAC | 374 | 473 | -9.4 | 2,109 | 2,208 |
| EMEA | 1,276 | 1,255 | 8.8 | 5,197 | 5,176 |
| Total | 2,774 | 2,730 | 13.3 | 11,597 | 11,553 |
| Net sales regions, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- | --- |
| Americas | 983 | 1,028 | 10.5 | 4,088 | 4,133 |
| APAC | 404 | 510 | -10.3 | 2,305 | 2,412 |
| EMEA | 1,041 | 1,056 | 4.4 | 5,236 | 5,251 |
| Total | 2,428 | 2,595 | 4.0 | 11,629 | 11,796 |
| Net sales specified by capital goods and recurring revenue, SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Org Δ, % | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- | --- |
| Capital goods | 1,025 | 1,132 | -0.7 | 5,722 | 5,829 |
| Recurring revenue^{1)} | 1,402 | 1,463 | 7.6 | 5,907 | 5,967 |
| Total | 2,428 | 2,595 | 4.0 | 11,629 | 11,796 |
1) Consumables, service and spare parts
Earnings trend
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2026 | 2025 |
| Net sales | 2,428 | 2,595 | 11,629 | 11,796 |
| Adjusted gross profit | 1,037 | 1,068 | 5,002 | 5,034 |
| Margin, % | 42.7 | 41.2 | 43.0 | 42.7 |
| Adjusted EBITDA | 222 | 205 | 1,713 | 1,697 |
| Margin, % | 9.1 | 7.9 | 14.7 | 14.4 |
| Depreciation, amortization and write-downs of intangible assets and tangible assets | -147 | -157 | -609 | -619 |
| Adjusted EBITA | 75 | 49 | 1,104 | 1,077 |
| Margin, % | 3.1 | 1.9 | 9.5 | 9.1 |
1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability
Events in the business area in the quarter
- Product Area Digital Health Solutions grew order intake by more than 30% in the quarter. There was especially great momentum for the OR Integration product line with significant wins in the UK and Central Eastern Europe, which confirms the solid market success for the Matrix Tegris system.
8 | Q1 2026 Report
GETINGE
Other information
Events after the end of the reporting period
The geopolitical uncertainty and changing global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations.
Seasonal variations
Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.
Transactions with related parties
Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.
Forward-looking information
This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.
Update of Organic change key ratio
The definition of Organic change has been updated from the first quarter of 2026 to also adjust for phase-outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase-outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge's website under Reports and Presentations, https://www.getinge.com/int/company/investors/reports-presentations/. Surgical Perfusion's sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.
Getinge's financial targets 2024-2028 and dividend policy
- Average adjusted earnings per share growth: >12%*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.
Getinge's sustainability targets
Environment
- Reduce Scope 1 and 2 emissions by 90% by 2030**
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050**
- Reduce energy consumption in production by 20% by 2030**
- Reduce water consumption in sites located in water scarce areas by 20% by 2030**
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled
Social
- Employee engagement: >70%
9 | Q1 2026 Report
GETINGE
- Maintain work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) at less than 1.
- Ensure equal employment opportunity and non-discrimination across all levels of the organization Follow-up % female vs male managers and employees
- Quality regulatory compliance, audit results/inspection: <1.2 deviation
Governance
- All employees are properly trained in Business ethics
Base year 2023
*Base year 2021
10 | Q1 2026 Report
GETINGE
Risk management
Getinge operates in a global market and has a strong presence in a large number of countries. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products and services that improve people's quality of life.
Risk management framework
Getinge's three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks.
Getinge has an Enterprise Risk Management (ERM) process covering all business areas, the global sales and service organization and the corporate and Group support functions. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit.
Risk assessment
The most relevant risks are presented in Getinge's 2025 Annual Report, meaning that the list does not constitute a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:
- External – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities.
- Operational – Risks that are largely controllable and preventable, mainly related to processes, assets and employees.
- Strategic – risks that make it more difficult to achieve the strategic targets. These risks are to be managed by balancing risks and the potential for maximizing advantages.
11 | Q1 2026 Report
GETINGE
Assurance
The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.
Gothenburg, April 21, 2026
| Johan Malmquist
Chairman,
AGM-elected Board member | Carl Bennet
Vice Chairman,
AGM-elected Board member | Johan Bygge
AGM-elected Board member |
| --- | --- | --- |
| Cecilia Daun Wennborg
AGM-elected Board member | Ulrika Dellby
AGM-elected Board member | Dan Frohm
AGM-elected Board member |
| Mattias Perjos
President & CEO,
AGM-elected Board member | Malin Persson
AGM-elected Board member | Kristian Samuelsson
AGM-elected Board member |
| Fredrik Brattborn
Board member
Representative of the Swedish
Metalworkers' Union | Åke Larsson
Board member
Representative of the Swedish
Association of Graduate
Engineers | |
12 | Q1 2026 Report
GETINGE
Consolidated financial statements
Condensed consolidated income statement
| SEK M | Note | Jan-Mar 2026 | Jan-Mar 2025 | Jan-Dec 2025 |
|---|---|---|---|---|
| Net sales | 2, 3 | 7,443 | 8,320 | 34,969 |
| Cost of goods sold | -3,837 | -4,225 | -18,315 | |
| Gross profit | 2, 3, 4 | 3,606 | 4,095 | 16,654 |
| Selling expenses | -1,430 | -1,586 | -6,050 | |
| Administrative expenses | -1,122 | -1,180 | -4,587 | |
| Research and development costs | -328 | -318 | -1,452 | |
| Acquisition costs | -18 | -2 | -24 | |
| Restructuring costs | -12 | -296 | -374 | |
| Other operating income and expenses | 12 | -115 | -379 | |
| Operating profit (EBIT) | 3, 4 | 707 | 598 | 3,789 |
| Net financial items | 3 | -135 | -170 | -644 |
| Profit after financial items | 3 | 573 | 428 | 3,145 |
| Taxes | -170 | -124 | -869 | |
| Net profit for the period | 402 | 304 | 2,276 | |
| Attributable to: | ||||
| Parent Company shareholders | 401 | 300 | 2,258 | |
| Non-controlling interests | 1 | 4 | 17 | |
| Net profit for the period | 402 | 304 | 2,276 | |
| Earnings per share, SEK 1) 2) | 1.47 | 1.10 | 8.29 | |
| Weighted average number of shares for calculation of earnings per share (000s) | 272,370 | 272,370 | 272,370 |
1) Before and after dilution
2) Attributable to the Parent Company shareholders
Consolidated statement of comprehensive income
| SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Jan-Dec 2025 |
|---|---|---|---|
| Net profit for the period | 402 | 304 | 2,276 |
| Other comprehensive income | |||
| Items that cannot be restated in profit for the period | |||
| Actuarial gains/losses pertaining to defined-benefit pension plans | 73 | 102 | 165 |
| Tax attributable to items that cannot be restated in profit | -21 | -29 | -45 |
| Items that can later be restated in profit for the period | |||
| Translation differences | 975 | -2,430 | -4,160 |
| Hedging of net investments | 140 | -518 | -754 |
| Cash flow hedges | 8 | 2 | -5 |
| Tax attributable to items that can be restated in profit | -30 | 106 | 156 |
| Other comprehensive income for the period, net after tax | 1,144 | -2,766 | -4,643 |
| Total comprehensive income for the period | 1,546 | -2,462 | -2,367 |
| Comprehensive income attributable to: | |||
| Parent Company shareholders | 1,545 | -2,472 | -2,373 |
| Non-controlling interests | 1 | 10 | 6 |
| Total comprehensive income for the period | 1,546 | -2,462 | -2,367 |
13 | Q1 2026 Report
GETINGE
Condensed consolidated balance sheet
| SEK M | Note | March 31 2026 | March 31 2025 | December 31 2025 |
|---|---|---|---|---|
| Intangible assets | 34,656 | 35,991 | 33,513 | |
| Tangible assets | 3,524 | 3,598 | 3,469 | |
| Right-of-use assets | 1,498 | 1,590 | 1,470 | |
| Financial assets | 67 | 49 | 34 | |
| Deferred tax assets | 835 | 878 | 792 | |
| Total non-current assets | 40,579 | 42,106 | 39,278 | |
| Inventories | 6,578 | 6,650 | 6,018 | |
| Accounts receivable | 4,931 | 5,265 | 5,782 | |
| Other current receivables | 1,908 | 2,046 | 2,026 | |
| Cash and cash equivalents | 7 | 4,020 | 4,203 | 3,401 |
| Total current assets | 17,437 | 18,164 | 17,227 | |
| TOTAL ASSETS | 58,016 | 60,270 | 56,505 | |
| Equity | 31,040 | 30,748 | 29,494 | |
| Provisions for pensions, interest-bearing | 7 | 2,300 | 2,452 | 2,358 |
| Lease liabilities, long-term | 7 | 1,048 | 1,145 | 1,029 |
| Interest-bearing liabilities, long-term | 7 | 7,953 | 8,118 | 7,893 |
| Deferred tax liabilities | 1,814 | 1,998 | 1,754 | |
| Other provisions, long-term | 460 | 420 | 485 | |
| Other non-interest-bearing liabilities, long-term | 473 | 1,501 | 452 | |
| Total long-term liabilities | 14,049 | 15,633 | 13,970 | |
| Lease liabilities, current | 7 | 461 | 450 | 452 |
| Interest-bearing liabilities, current | 7 | 1,526 | 1,769 | 1,510 |
| Other provisions, current | 1,592 | 1,939 | 1,564 | |
| Accounts payable | 2,063 | 2,221 | 2,118 | |
| Other non-interest-bearing liabilities, current | 7,286 | 7,509 | 7,398 | |
| Total current liabilities | 12,927 | 13,888 | 13,042 | |
| TOTAL EQUITY AND LIABILITIES | 58,016 | 60,270 | 56,505 |
Changes in equity for the Group
| SEK M | Share capital | Other capital provided | Reserves^{1)} | Retained earnings | Total | Non-controlling interests | Total equity |
|---|---|---|---|---|---|---|---|
| Opening balance at January 1, 2025 | 136 | 6,789 | 5,752 | 20,328 | 33,005 | 205 | 33,210 |
| Total comprehensive income for the period | - | - | -2,825 | 373 | -2,452 | -10 | -2,462 |
| Closing balance at March 31, 2025 | 136 | 6,789 | 2,927 | 20,701 | 30,553 | 195 | 30,748 |
| Opening balance at January 1, 2025 | 136 | 6,789 | 5,752 | 20,328 | 33,005 | 205 | 33,210 |
| Total comprehensive income for the period | - | - | -4,752 | 2,378 | -2,373 | 6 | -2,367 |
| Dividend | - | - | - | -1,253 | -1,253 | -14 | -1,267 |
| Transactions with non-controlling interests | - | - | - | 50 | 50 | -133 | -83 |
| Closing balance at December 31, 2025 | 136 | 6,789 | 1,000 | 21,504 | 29,430 | 64 | 29,494 |
| Opening balance at January 1, 2026 | 136 | 6,789 | 1,000 | 21,504 | 29,430 | 64 | 29,494 |
| Total comprehensive income for the period | - | - | 1,093 | 452 | 1,545 | 1 | 1,546 |
| Closing balance at March 31, 2026 | 136 | 6,789 | 2,093 | 21,957 | 30,975 | 65 | 31,040 |
1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.
14 | Q1 2026 Report
GETINGE
Condensed consolidated cash flow statement
| SEK M | Note | Jan-Mar 2026 | Jan-Mar 2025 | Jan-Dec 2025 |
|---|---|---|---|---|
| Operating activities | ||||
| Operating profit (EBIT) | 707 | 598 | 3,789 | |
| Add-back of depreciation, amortization and write-downs | 4 | 484 | 566 | 2,250 |
| Other non-cash items | 2 | 11 | 164 | |
| Add-back of restructuring costs^{1)} | 12 | 276 | 362 | |
| Paid restructuring costs | -67 | -105 | -338 | |
| Financial items^{2)} | -117 | -118 | -516 | |
| Taxes paid | -157 | -95 | -574 | |
| Cash flow before changes in working capital | 864 | 1,132 | 5,137 | |
| Changes in working capital | ||||
| Inventories | -347 | -684 | -465 | |
| Operating receivables | 1,171 | 766 | -218 | |
| Operating liabilities^{3)} | -582 | -744 | -504 | |
| Cash flow from operating activities | 1,106 | 470 | 3,949 | |
| Investing activities | ||||
| Acquisition of operations | 9 | - | -91 | -1,663 |
| Investments in intangible assets and tangible assets | -268 | -313 | -1,314 | |
| Divestment of non-current assets | 4 | 3 | 17 | |
| Cash flow from investing activities | -264 | -401 | -2,960 | |
| Financing activities | ||||
| Change in interest-bearing liabilities | -68 | 1,266 | 1,000 | |
| Depreciation of lease liabilities | -122 | -129 | -501 | |
| Change in long-term receivables | - | -1 | 3 | |
| Dividend paid | - | - | -1,267 | |
| Cash flow from financing activities | -189 | 1,136 | -765 | |
| Cash flow for the period | 653 | 1,205 | 224 | |
| Cash and cash equivalents at the beginning of the period | 3,401 | 2,961 | 2,961 | |
| Translation differences | -34 | 37 | 216 | |
| Cash and cash equivalents at the end of the period | 4,020 | 4,203 | 3,401 |
1) Excluding write-downs on non-current assets
2) Of which interest paid and received in the quarter amounted to SEK -110 M (-113) and other financial items to SEK -7 M (-5)
15 | Q1 2026 Report
GETINGE
Note 1 Accounting policies
The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2025 Annual Report and should be read in conjunction with that Annual Report.
For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.
Note 2 Net sales
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| Net sales, SEK M | 2026 | 2025 | 2025 |
| Capital goods | 2,078 | 2,481 | 11,968 |
| Recurring revenue | |||
| Product sales | 3,788 | 4,150 | 16,185 |
| Service assignments incl. spare parts | 1,577 | 1,689 | 6,815 |
| Total recurring revenue | 5,365 | 5,839 | 23,001 |
| Total | 7,443 | 8,320 | 34,969 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| --- | --- | --- | --- |
| Net sales, SEK M | 2026 | 2025 | 2025 |
| Revenue recognized at a point in time | |||
| Acute Care Therapies | 3,745 | 4,504 | 17,499 |
| Life Science | 828 | 800 | 3,386 |
| Surgical Workflows | 1,923 | 2,090 | 9,626 |
| Total revenue recognized at a point in time | 6,496 | 7,394 | 30,512 |
| Revenue recognized over time | |||
| Acute Care Therapies | |||
| Service | 243 | 253 | 1,068 |
| Profit from ongoing projects | 1 | - | - |
| Other revenue recognized over time | 24 | 18 | 108 |
| Total Acute Care Therapies | 268 | 271 | 1,176 |
| Life Science | |||
| Service | 63 | 63 | 260 |
| Profit from ongoing projects | 111 | 87 | 852 |
| Other revenue recognized over time | - | 0 | 0 |
| Total Life Science | 175 | 150 | 1,112 |
| Surgical Workflows | |||
| Service | 454 | 445 | 1,870 |
| Profit from ongoing projects | 15 | 29 | 139 |
| Other revenue recognized over time | 36 | 30 | 160 |
| Total Surgical Workflows | 505 | 505 | 2,170 |
| Total revenue recognized over time | 947 | 925 | 4,457 |
| Total revenue recognized at a point in time and over time | 7,443 | 8,320 | 34,969 |
For further information about the distribution of sales for each business area, see pages 6-8.
16 | Q1 2026 Report
GETINGE
Note 3 Segment overview
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| Net sales, SEK M | 2026 | 2025 | 2025 |
| Acute Care Therapies | 4,012 | 4,775 | 18,675 |
| Life Science | 1,003 | 950 | 4,498 |
| Surgical Workflows | 2,428 | 2,595 | 11,796 |
| Total | 7,443 | 8,320 | 34,969 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| Gross profit, SEK M | 2026 | 2025 | 2025 |
| Acute Care Therapies | 2,305 | 2,769 | 10,420 |
| Life Science | 351 | 346 | 1,556 |
| Surgical Workflows | 950 | 979 | 4,679 |
| Total | 3,606 | 4,095 | 16,654 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| Operating profit (EBIT), SEK M | 2026 | 2025 | 2025 |
| Acute Care Therapies | 703 | 692 | 3,021 |
| Life Science | 80 | 38 | 470 |
| Surgical Workflows | 52 | -21 | 773 |
| Group functions and other (incl. eliminations)1) | -128 | -112 | -474 |
| Operating profit (EBIT) | 707 | 598 | 3,789 |
| Net financial items | -135 | -170 | -644 |
| Profit after financial items | 573 | 428 | 3,145 |
1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| Net sales, SEK M | 2026 | 2025 | 2025 |
| EMEA | 2,635 | 2,630 | 12,340 |
| of which, Sweden | 151 | 139 | 648 |
| Americas | 3,453 | 4,047 | 15,686 |
| of which, USA | 3,138 | 3,693 | 14,157 |
| APAC | 1,355 | 1,642 | 6,943 |
| Total | 7,443 | 8,320 | 34,969 |
Note 4 Depreciation, amortization and write-downs
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| SEK M | 2026 | 2025 | 2025 |
| Acquired intangible assets | -87 | -107 | -434 |
| Intangible assets | -130 | -164 | -643 |
| Right-of-use assets | -125 | -136 | -523 |
| Tangible assets | -142 | -159 | -650 |
| Total | -484 | -566 | -2,250 |
| Write-downs included in total | - | -20 | -166 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| --- | --- | --- | --- |
| SEK M | 2026 | 2025 | 2025 |
| Cost of goods sold | -223 | -242 | -953 |
| Selling expenses | -153 | -181 | -705 |
| Administrative expenses | -89 | -105 | -405 |
| Research and development costs | -19 | -17 | -175 |
| Restructuring costs | - | -20 | -12 |
| Total | -484 | -566 | -2,250 |
| Write-downs included in total | - | -20 | -166 |
17 | Q1 2026 Report
GETINGE
Note 5 Quarterly results
| Jan-Mar | Oct-Dec | Jul-Sep | Apr-Jun | Jan-Mar | Oct-Dec | Jul-Sep | Apr-Jun | |
|---|---|---|---|---|---|---|---|---|
| SEK M | 2026 | 2025 | 2025 | 2025 | 2025 | 2024 | 2024 | 2024 |
| Net sales | 7,443 | 10,186 | 8,226 | 8,238 | 8,320 | 11,071 | 7,870 | 8,305 |
| Cost of goods sold | -3,837 | -5,382 | -4,411 | -4,296 | -4,225 | -6,018 | -4,315 | -4,394 |
| Gross profit | 3,606 | 4,803 | 3,815 | 3,941 | 4,095 | 5,053 | 3,556 | 3,911 |
| Operating expenses | -2,899 | -3,432 | -2,863 | -3,074 | -3,497 | -3,969 | -3,372 | -3,081 |
| Operating profit (EBIT) | 707 | 1,371 | 952 | 867 | 598 | 1,084 | 184 | 830 |
| Net financial items | -135 | -164 | -163 | -147 | -170 | -173 | -152 | -130 |
| Profit after financial items | 573 | 1,207 | 789 | 721 | 428 | 911 | 32 | 700 |
| Taxes | -170 | -338 | -214 | -194 | -124 | -243 | -24 | -187 |
| Net profit for the period | 402 | 869 | 576 | 527 | 304 | 668 | 8 | 513 |
Note 6 Adjustment items
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| Adjusted EBITA, SEK M | 2026 | 2025 | 2025 |
| Acute Care Therapies | 763 | 1,012 | 3,763 |
| Life Science | 96 | 53 | 490 |
| Surgical Workflows | 75 | 49 | 1,077 |
| Group functions and other (incl. eliminations) | -110 | -110 | -450 |
| Total | 824 | 1,003 | 4,880 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| Adjustments of EBITA, SEK M | 2026 | 2025 | 2025 |
| Specification of items affecting comparability that impact EBITA | |||
| Restructuring costs, Acute Care Therapies | -5 | -251 | -293 |
| Restructuring costs, Life Science | -4 | 0 | -22 |
| Restructuring costs, Surgical Workflows | -4 | -45 | -59 |
| Write-down of R&D, Acute Care Therapies | - | - | -28 |
| Write-down of R&D, Surgical Workflows | - | - | -107 |
| Increased provision for contingent consideration, Acute Care Therapies1) | - | - | -179 |
| Dissolution of provisions for contingent consideration, Life Science1) | - | - | 55 |
| Group functions and other (incl. eliminations) | -18 | -2 | -24 |
| Total | -30 | -298 | -656 |
| Items affecting comparability per segment | |||
| Acute Care Therapies | -5 | -251 | -500 |
| Life Science | -4 | 0 | 33 |
| Surgical Workflows | -4 | -45 | -166 |
| Group functions and other (incl. eliminations) | -18 | -2 | -24 |
| Total | -30 | -298 | -656 |
1) Reported in Other operating income and operating expenses
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| EBITA, SEK M | 2026 | 2025 | 2025 |
| Acute Care Therapies | 758 | 761 | 3,264 |
| Life Science | 92 | 53 | 523 |
| Surgical Workflows | 71 | 4 | 911 |
| Group functions and other (incl. eliminations) | -128 | -112 | -474 |
| Total | 794 | 705 | 4,223 |
| Jan-Mar | Jan-Mar | Jan-Dec | |
| --- | --- | --- | --- |
| Adjustments of EBIT, SEK M | 2026 | 2025 | 2025 |
| Items affecting comparability that impact EBITA (according to above) | -30 | -298 | -656 |
| Items affecting comparability that impact EBIT but not EBITA1) | - | - | -48 |
| Total | -30 | -298 | -704 |
1) Write-down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| Effect of adjustment of tax, SEK M | 2026 | 2025 | 2025 |
| Amortization and write-down of acquired intangible assets1) | 87 | 107 | 386 |
| Items affecting comparability | 30 | 298 | 704 |
| Adjustment items, total | 117 | 405 | 1,091 |
18 | Q1 2026 Report
GETINGE
| Tax on adjustment items2) | -29 | -112 | -273 |
|---|---|---|---|
| Adjustment for tax items affecting comparability | - | - | - |
| Total | -29 | -112 | -273 |
1) Excluding write-downs classified as items affecting comparability
2) Tax effect on tax deductible adjustment items
Note 7 Consolidated net interest-bearing debt
| March 31 | March 31 | December 31 | |
|---|---|---|---|
| SEK M | 2026 | 2025 | 2025 |
| Interest-bearing liabilities, current | 1,526 | 1,769 | 1,510 |
| Interest-bearing liabilities, long-term | 7,953 | 8,118 | 7,893 |
| Provisions for pensions, interest-bearing | 2,300 | 2,452 | 2,358 |
| Lease liabilities, current | 461 | 450 | 452 |
| Lease liabilities, long-term | 1,048 | 1,145 | 1,029 |
| Interest-bearing liabilities | 13,288 | 13,934 | 13,241 |
| Less cash and cash equivalents | -4,020 | -4,203 | -3,401 |
| Net interest-bearing cash/debt | 9,268 | 9,731 | 9,840 |
Note 8 Key figures for the Group
| Financial and operative key figures | Jan-Mar 2026 | Jan-Mar 2025 | Jan-Dec 2025 |
|---|---|---|---|
| Key figures based on Getinge's financial targets | |||
| Adjusted earnings per share1), SEK | 1.8 | 2.18 | 11.29 |
| Growth in adjusted earnings per share1), % | -17.7 | 13.5 | -3.7 |
| Other operative and financial key figures | |||
| Organic growth in order intake, % | 3.9 | 2.9 | 3.5 |
| Organic growth in net sales, % | 0.8 | 6.2 | 4.9 |
| Gross margin, % | 48.4 | 49.2 | 47.6 |
| Selling expenses, % of net sales | 19.2 | 19.1 | 17.3 |
| Administrative expenses, % of net sales | 15.1 | 14.2 | 13.1 |
| Research and development costs, gross as a % of net sales | 6.5 | 5.9 | 6.0 |
| Operating margin, % | 9.5 | 7.2 | 10.8 |
| EBITDA, SEK M | 1,191 | 1,164 | 6,039 |
| Average number of shares, thousands | 272,370 | 272,370 | 272,370 |
| Number of shares at the end of the period, thousands | 272,370 | 272,370 | 272,370 |
| Interest-coverage ratio, multiple | 11.1 | 12.0 | 11.2 |
| Net debt/equity ratio, multiple | 0.30 | 0.32 | 0.33 |
| Net debt/Rolling 12m adjusted EBITDA, multiple | 1.5 | 1.4 | 1.5 |
| Capital employed, SEK M | 40,260 | 41,365 | 40,934 |
| Return on capital employed, % | 10.8 | 11.3 | 11.0 |
| Return on equity, % | 7.9 | 4.7 | 7.5 |
| Equity/assets ratio, % | 53.5 | 51.0 | 52.2 |
| Equity per share, SEK | 113.96 | 112.89 | 108.28 |
| Number of employees | 11,754 | 11,827 | 11,670 |
1) Before and after dilution
19 | Q1 2026 Report
GETINGE
Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.
| Jan-Mar | |
|---|---|
| Calculation of organic net sales | 2026 |
| Net sales Jan-Mar 2025 | 8,320 |
| Adjustment of: | |
| Divested operations and products as well as products being phased out, in the comparative period | -59 |
| Net sales Jan-Mar 2025 adjusted for divested operations and products | 8,261 |
| Net Sales Jan-Mar 2026 | 7,443 |
| Adjustment of: | |
| Currency translation | 901 |
| Acquired and divested operations and products | -17 |
| Net sales, organic | 8,327 |
| Jan-Mar | |
| --- | --- |
| Adjusted gross profit, SEK M | 2026 |
| Gross profit | 3,606 |
| Add-back of: | |
| Depreciation, amortization and write-downs of intangible assets and tangible assets | 223 |
| Other items affecting comparability | - |
| Adjustment for write-downs included in other items affecting comparability | - |
| Adjusted gross profit | 3,828 |
| Jan-Mar | |
| --- | --- |
| Adjusted EBITDA, SEK M | 2026 |
| Operating profit (EBIT) | 707 |
| Add-back of: | |
| Depreciation, amortization and write-downs of intangible assets and tangible assets | 397 |
| Amortization and write-down of acquired intangible assets | 87 |
| Other items affecting comparability | - |
| Acquisition and restructuring costs | 30 |
| Adjustment for write-downs included in other items affecting comparability and restructuring costs | - |
| Adjusted EBITDA | 1,222 |
| Jan-Mar | |
| --- | --- |
| Adjusted EBITA, SEK M | 2026 |
| Operating profit (EBIT) | 707 |
| Add-back of: | |
| Amortization and write-down of acquired intangible assets | 87 |
| Other items affecting comparability | - |
| Acquisition and restructuring costs | 30 |
| Adjusted EBITA | 824 |
| Jan-Mar | |
| --- | --- |
| Adjusted EBIT, SEK M | 2026 |
| Operating profit (EBIT) | 707 |
| Add-back of: | |
| Other items affecting comparability | - |
| Acquisition and restructuring costs | 30 |
| Adjusted EBIT | 738 |
| Jan-Mar | |
| --- | --- |
| Adjusted net profit for the period, SEK M | 2026 |
| Net profit for the period | 402 |
| Add-back of: | |
| Amortization and write-down of acquired intangible assets | 87 |
| Other items affecting comparability | - |
20 | Q1 2026 Report
GETINGE
| Acquisition and restructuring costs | 30 | 298 | 130 | 397 |
|---|---|---|---|---|
| Tax items affecting comparability | - | - | - | - |
| Tax on add-back items | -29 | -112 | -191 | -273 |
| Adjusted net profit for the period | 490 | 597 | 2,986 | 3,093 |
| The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information: | Jan-Mar 2026 | Jan-Mar 2025 | R12 Mar 2026 | Jan-Dec 2025 |
| --- | --- | --- | --- | --- |
| Earnings (numerator), SEK M | ||||
| Adjusted net profit for the period | 490 | 597 | 2,986 | 3,093 |
| Adjusted net profit for the period attributable to non-controlling interest | -1 | -4 | -14 | -17 |
| Adjusted net profit for the period attributable to the Parent Company shareholders, which forms the basis for calculation of adjusted earnings per share | 489 | 593 | 2,972 | 3,076 |
| Jan-Mar | Jan-Mar | R12 Mar | Jan-Dec | |
| Number of shares (denominator) | 2026 | 2025 | 2026 | 2025 |
| Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands) | 272,370 | 272,370 | 272,370 | 272,370 |
| Adjusted earnings per share, SEK | 1.80 | 2.18 | 10.91 | 11.29 |
| The calculation of adjusted EBITA margin, adjusted for currency impact and tariff costs, is based on the following information: | Jan-Mar 2026 | |||
| --- | --- | |||
| Adjusted EBITA (numerator), SEK M | ||||
| Adjusted EBITA | 824 | |||
| Add-back of: | ||||
| Currency impact | 122 | |||
| Tariffs costs | 104 | |||
| Adjusted EBITA, adjusted for currency impact and tariff costs | 1,050 | |||
| Jan-Mar 2026 | ||||
| Net sales (denominator) | ||||
| Net sales | 7,443 | |||
| Add-back of: | ||||
| Currency impact | 901 | |||
| Net sales, adjusted for currency impact | 8,344 | |||
| Adjusted EBITA margin, adjusted for currency impact and tariff costs, % | 12.6 |
Note 9 Acquisitions
No acquisitions took place during the first quarter that had a material impact on the Group's financial earnings and position.
Contingent considerations
Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.
21 | Q1 2026 Report
GETINGE
| March 31 | March 31 | December 31 | |
|---|---|---|---|
| Contingent considerations | 2026 | 2025 | 2025 |
| Opening balance | 1,444 | 3,280 | 3,280 |
| Business combinations | - | - | - |
| Dissolution of provision | - | - | -55 |
| Fair value adjustments recognized in profit or loss | - | 5 | 184 |
| Payments | - | -110 | -1,599 |
| Discount effect | 15 | 31 | 77 |
| Translation differences | 63 | -291 | -443 |
| Closing balance | 1,522 | 2,915 | 1,444 |
Parent Company financial statements
Condensed Parent Company's income statement
| SEK M | Jan-Mar 2026 | Jan-Mar 2025 | Jan-Dec 2025 |
|---|---|---|---|
| Net sales | 95 | 107 | 348 |
| Administrative expenses | -138 | -88 | -397 |
| Operating profit/loss | -43 | 19 | -49 |
| Result from participations in Group companies1) | - | - | 2,134 |
| Interest income and other similar income2) | 5 | 17 | 55 |
| Interest expenses and other similar expenses2) | -49 | -55 | -220 |
| Profit/loss after financial items | -87 | -19 | 1,920 |
| Appropriations | - | - | 60 |
| Taxes | 9 | -4 | -24 |
| Net profit/loss for the period3) | -78 | -23 | 1,956 |
1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year
2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies
3) Comprehensive income for the period corresponds to net profit for the period
22 | Q1 2026 Report
GETINGE
Condensed Parent Company's balance sheet
| SEK M | March 31 2026 | March 31 2025 | December 31 2025 |
|---|---|---|---|
| Assets | |||
| Tangible assets | 1 | 2 | 1 |
| Participations in Group companies | 32,256 | 29,582 | 31,572 |
| Deferred tax assets | 106 | 95 | 97 |
| Current receivables from Group companies | 207 | 1,797 | 974 |
| Current receivables | 27 | 43 | 40 |
| Cash and bank balances | 0 | 903 | 2 |
| Total assets | 32,597 | 32,422 | 32,687 |
| Equity and liabilities | |||
| Equity | 26,294 | 25,645 | 26,372 |
| Long-term liabilities | 5,394 | 5,093 | 5,394 |
| Other provisions | 22 | 20 | 18 |
| Current liabilities to Group companies | 1 | 1 | 7 |
| Current liabilities | 885 | 1,663 | 896 |
| Total equity and liabilities | 32,597 | 32,422 | 32,687 |
23 | Q1 2026 Report
GETINGE
Definitions
Financial terms
Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.
Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.
Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.
Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.
Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.
Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.
Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.
Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.
Capital goods: Durable products that are not consumed when used.
Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.
Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.
EBIT: Operating profit.
EBITA margin: EBITA in relation to net sales.
EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.
EBITDA margin: EBITDA in relation to net sales.
EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.
Equity per share: Equity in relation to the number of shares at the end of the period.
Equity/assets ratio: Equity in relation to total assets.
Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.
Gross margin: Gross profit in relation to net sales.
Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.
Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.
Net debt/equity ratio: Net interest-bearing debt in relation to equity.
Operating liabilities: Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).
Operating margin: Operating profit (EBIT) in relation to net sales.
Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).
Organic change: A financial change adjusted for currency, acquisitions and divestments of operations.
Adjusted to the following from first quarter of 2026: A financial change adjusted for currency, acquisitions and divestments of operations and phase-out of product categories.
Recurring revenue: Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.
Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.
Return on equity: Rolling 12 months' profit after tax in relation to average equity.
Sustainability terms
Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.
Employee engagement: The engagement score in Getinge's employee survey.
ESRS: European Sustainability Reporting Standards.
Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.
REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.
Scope 1 & 2: Carbon emissions from production (in ton CO₂ equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.
Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.
WRAR (Work Related Accident Rate): The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.
Medical terms
Cardiopulmonary: Pertaining or belonging to both heart and lung.
Cardiovascular: Pertaining or belonging to both heart and blood vessels.
DPTE®-BetaBags: Bag that ensures contamination-free transfer of components.
ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.
24 | Q1 2026 Report
GETINGE
Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.
Endovascular: Vascular treatment using catheter technologies.
EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.
Extracorporeal life support (ECLS): Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.
Grafts: Artificial vascular implants.
Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.
Low temperature sterilization: A device used to sterilize surgical instruments which
cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.
NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.
Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.
Stent: A tube for endovascular widening of blood vessels.
Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.
Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.
Ventilator: Medical device to help patients breath.
Vessel harvesting: The name of the process for removing blood vessels from the body.
WIS: The product category of washers, isolators and sterilizers.
Geographic areas
Americas: North, South and Central America.
APAC: Asia and Pacific (excluding Middle East).
EMEA: Europe, Middle East and Africa.
25 | Q1 2026 Report
GETINGE
Teleconference
A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on April 21, 2026 at 1:00–2:00 p.m. CEST.
Fund managers, analysts and the media are invited to the teleconference.
Register via https://events.inderes.com/getinge/q1-report-2026/dial-in to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.
A presentation will be held during the telephone conference. To access the presentation, click on https://events.inderes.com/getinge/q4-report-2025/dial-in. A recording will be available via https://getinge.events.inderes.com/q1-report-2026 for three years.
Financial information
Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:
April 21, 2026 Annual General Meeting
July 17, 2026 Q2 Report 2026
October 20, 2026 Q3 Report 2026
January 26, 2027 Q4 and Year-end report 2026
Contact
David Kördel, Head of Investor Relations
+46 (0)10 335 0077
[email protected]
This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on April 21, 2026 at 12:00 p.m. CEST.
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries. Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.
Getinge AB (publ) | Lindholmspiren 7A, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: [email protected] | Corp. Reg. No.: 556408-5032 | www.getinge.com
26 | Q1 2026 Report